During the past several decades, a large and growing number of studies have examined the association between potential risk markers and adverse outcomes in patients with cardiovascular diseases, including heart failure with preserved ejection fraction (HFpEF). Identification of novel risk markers in clinical syndromes such as HFpEF is important because it may (1) elucidate novel biological mechanisms, (2) inform pathophysiology of disease progression, (3) identify potential therapeutic targets, and/or (4) assist with risk prediction.
Shah SJ. Risk Marker Fatigue—Is There an Actionable Outcome? JAMA Cardiol. Published online November 18, 2020. doi:10.1001/jamacardio.2020.5616
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: